ZVRA Zevra Corp: Year-over-year earnings per share growth for the last twelve months

Official company branding of Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics (ZVRA) demonstrates recession resilience through the commercialization of orphan drugs. The quarterly EPS change reflects the clarity of the fundamental trend, recording the metric at 2772.80. Growth is supported by partnerships with scientific foundations to identify new molecular applications. Operational stability is ensured by an asset-light model, outsourcing capsule production to specialized contract manufacturing organizations.

Zevra Therapeutics, Inc. (ZVRA) Earnings per share growth in annualized terms for the last twelve months: for the period 04/28/2023 - 11/17/2026

Analytical breakdowns for Zevra Therapeutics

- share price and consensus valuation forecast:
Fundamental company analysis:zevra.com, ZVRA
Manufactured product of Zevra Corp

For Zevra Therapeutics (ZVRA), which is scaling sales of orphan drugs, profit dynamics are critical during the transition to commercialization. The quarterly EPS growth rate measures the percentage change in net income per share relative to the same period last year. The current value of 2772.80 reflects the efficiency of the operating model. Analysis of this chart allows for the identification of hidden imbalances in US expansion costs. A stable trend confirms the business's resilience to external shocks.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Edgewise Pharma EWTX|Rapport Corp - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Contineum Therapeutics, Inc.|LRMR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Capricor Therapeutics CAPR|Year-over-year net earnings per share growth for the last 12 months TRDA|Earnings per share growth in annualized terms for the last twelve months Channel PTHS|Year-over-year earnings per share growth for the last twelve months MediciNova Inc. (MNOV)|SER - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics Inc)|ProMIS Neurosciences (PMN) - Earnings per share growth in annualized terms for the last twelve months|Apimeds Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AEON Biopharma, Inc.|NLSP (NLS Pharma) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata